Lung cancer staging: a true story  by Rabe, Klaus F
Comment
258 www.thelancet.com/respiratory   Vol 3   April 2015
Lung cancer staging: a true story
In The Lancet Respiratory Medicine, Neal Navani and 
colleagues report data from a multicentre trial to 
assess the use of endobronchial ultrasound (EBUS) 
transbronchial aspiration (TBNA) for the staging of 
lung cancer.1 In 2008, when recruitment for this trial 
started, 1·6 million new cases of lung cancer occurred 
worldwide, accounting for 13% of all cancers. During 
the same period, 1·4 million people died of the disease, 
representing 18% of all cancer deaths.2 Most lung 
cancers (about 80%) are non-small-cell lung cancers 
(NSCLC),3 for which surgery is a curative option. 
However, more than 65% of patients present with 
locally advanced or metastatic disease4 at the time 
of diagnosis, and 40% of patients with NSCLC have 
distant metastases at the time of presentation.5 
An updated lung cancer staging system based on an 
up-to-date database6 and an up-to-date histological 
classiﬁ cation system7 are pivotal for the management 
of the disease. Although most patients are initially 
diagnosed via a conventional chest radiograph, 
various technologies are now available for further 
staging of patients. 18F-ﬂ uorodeoxyglucose (18F-FDG) 
PET has an increasing role for the staging of lung 
cancer and might in the future have a major role in the 
prediction and assessment of treatment responses.8 
The sensitivity of the method is variable and depends 
on the generation of scanners used, ranging from 
68% to 100%.9 The importance of the method lies in 
its high negative predictive value and the detection 
of distant metastases, which reduces unnecessary 
thoracotomies.10 These outcomes form the basis 
for the clinical strategy to proceed with surgical 
resection immediately after a negative 18F-FDG PET 
scan; positive responses mandate tissue veriﬁ cation 
because of the fairly low positive predictive value. 
Mediastinoscopy, still widely advocated as the surgical 
gold standard for tissue veriﬁ cation, has a sensitivity of 
about 80%,11 and its use in the staging of lung cancer 
is decreasing in favour of new endoscopic ultrasound 
techniques such as EBUS and endo-oesophageal 
ultrasound (EUS). 
The endoscopic techniques have a high positive 
predictive value and a higher sensitivity than surgical 
staging, which means these techniques should 
now be the ﬁ rst step for tissue veriﬁ cation after a 
positive CT or ¹⁸F-FDG PET scan. Another substantial 
advantage of endoscopic techniques is the real-time 
biopsy sampling of suspect lesions, by contrast with 
conventional transbronchial ﬁ ne needle aspirations, 
and the immediate availability of cell material for 
on-site cytological assessment. Additionally, any 
cytological specimen obtained through endoscopic 
ultrasound devices can undergo molecular 
characterisation of tumour tissue through the analysis 
of tumour DNA.12
In their study,1 which included 133 patients recruited 
from six centres in the UK, Navani and colleagues 
investigated the role of EBUS-TBNA in patients with 
suspected stage I to IIIA lung cancer. Their ﬁ ndings 
lend support to previous data showing the usefulness 
of this technique from larger randomised trials,11,13 but 
adds the important result that, under the described 
trial circumstances, time to treatment decision was 
signiﬁ cantly shorter in the EBUS group (14 days, 95% 
CI 14–15) than in the group that had full conventional 
diagnosis and staging (29 days, 23–35; hazard ratio 
1·98 [1·39–2·82], p<0·0001). The investigators 
conclude—correctly—that clinicians should follow 
present guideline recommendations to use EBUS-
TBNA for the staging of non-small-cell lung cancer, 
and support the claim already made by others11 that 
this procedure should be the ﬁ rst diagnostic step. In 
the study, 30 patients (45%) in the EBUS-TBNA group 
did not need any other diagnostic step, compared with 
eight (12%) in the conventional diagnosis group.
The study was designed as a pragmatic, randomised 
controlled trial. This approach, in which exclusion 
criteria are minimised, should allow for the inclusion 
of heterogeneous groups of patients with a wide 
range of diagnoses, with patient groups deﬁ ned by 
presentation rather than diagnosis—a theoretical 
advantage of the study design that was not fully taken 
advantage of by Navani and colleagues.1  Pragmatic, 
randomised clinical trials are necessary and ﬁ ndings 
from such studies are important when complex 
procedures are being assessed and when strict placebo 
groups are not an option. Frequently, as in the present 
case, large, well controlled trials have already been 
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done and provide some evidence that still has to be 
translated into usual clinical care. However, pragmatic 
trials can have their own challenges related to patient 
recruitment, funding, and the stringency with which 
common practice is deﬁ ned. 
The number of patients recruited and randomly 
assigned during more than 3 years in Navani and 
colleagues’ study was surprisingly low (133); the 
partici pants are therefore unlikely to be consecutive 
cases, and this slow recruitment will have resulted 
in some bias in patient selection. According to a 
report14 from the UK Office for National Statistics, 
about 163 100 males and 159 800 females were newly 
diagnosed with cancer each year between 2008 and 
2010 in the UK. Lung cancer was the second most 
common newly diagnosed cancer in both males (mean 
23 398) and females (mean 18 766) in this period. 
These data represent age-standardised incidence rates 
of 60 new cases per 100 000 men, and 40 new cases 
per 100 000 women each year, which translate into a 
staggering mean number of deaths from lung cancer 
of 19 668 men and 15 374 women each year in the 
UK alone. These figures are alarming, and because 
smoking remains one of the most prominent risk 
factors for this devastating disease, public health and 
political efforts for education and tobacco control are 
more urgently needed than ever.
Undetected mediastinal metastases occur in up to 
28% of patients with lung cancer,10 and probably the 
most substantial advance in the staging of lung cancer 
has been the introduction, and by now widespread use, 
of transoesophageal (EUS) and transbronchial (EBUS) 
ultrasound for diagnosis and staging.13 Evidence from 
a meta-analysis15 suggests that the combination of 
EUS and EBUS investigations (sometimes done with 
an EBUS scope only) is more sensitive than either 
procedure alone, and this approach might qualify as the 
next gold standard for adequate lung cancer staging if 
these instruments and skills in these clinical techniques 
become available worldwide. 
For the early stages of lung cancer, the clinical 
landscape has permanently changed. The introduction 
of endoscopic ultrasound techniques such as 
EBUS-TBNA provides exact and minimally invasive 
mediastinal staging to be used for prognostication.11 
In view of the large and unremitting burden of lung 
cancer worldwide, efforts are needed to ensure that 
the equipment, knowledge, and skills necessary 
for the use of these approaches are available in all 
countries. 
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